Manufacturers submit New Drug Application to the FDA for relugolix for advanced prostate cancer

The dossier submission of this oral gonadotropin-releasing hormone antagonist was following positive results from the HERO phase III study which found a sustained testosterone suppression rate (to castrate levels) of 96.7% by week 48.

Biospace Inc.